L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure
Open Access
- 1 February 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (2) , 189-193
- https://doi.org/10.1023/a:1008368916800
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cerebrospinal Fluid Asparagine Concentrations After Escherichia coli Asparaginase in Children With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 1999
- Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL‐BFM treatment protocolsBritish Journal of Haematology, 1999
- Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemiaBritish Journal of Haematology, 1997
- L-asparagine-depletion: Another opinionAnnals of Oncology, 1997
- L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginaseAnnals of Oncology, 1996
- Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparationsEuropean Journal Of Cancer, 1996
- Loss of activity of Erwinia asparaginase on repeat applications.Journal of Clinical Oncology, 1995
- Comparative pharmacokinetic studies of three asparaginase preparations.Journal of Clinical Oncology, 1993
- Non‐randomised study comparing toxicity of escherichia coli and erwinia asparaginase in children with leukaemiaMedical and Pediatric Oncology, 1990
- Chemical and immunological characteristics of four different L‐asparaginase preparationsEuropean Journal of Haematology, 1989